Entrada Therapeutics, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Entrada is a preclinical-stage biotechnology company developing Endosomal Escape Vehicle (EEV) therapeutics. It reported no product sales and had not initiated clinical studies; its lead programs include ENTR-601-44 and ENTR-601-45 for Duchenne muscular dystrophy (DMD), and partnered candidate ENTR-701 for myotonic dystrophy type 1 (DM1).
Key financial metrics
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Collaboration revenue | $25.3 million | $0 |
| Research and development expense | $23.1 million | $15.7 million; up $7.4 million |
| General and administrative expense | $7.9 million | $6.4 million; up $1.5 million |
| Operating loss | $5.8 million | $22.2 million |
| Interest and other income | $2.7 million | $0.5 million |
| Income tax expense | $3.6 million | $0 |
| Net loss / loss per share | $6.7 million / $0.21 | $21.7 million / $0.69 |
| Operating cash flow | $203.4 million provided | $21.0 million used |
| Cash, cash equivalents and marketable securities | $411.6 million at March 31 | $188.7 million at December 31, 2022 |
At March 31, cash and cash equivalents were $227.6 million and marketable securities were $184.0 million; restricted cash of $4.0 million was separate. Current assets were $434.1 million and current liabilities $147.6 million. Total liabilities were $246.0 million, including $211.6 million of deferred revenue and operating lease obligations; the filing does not report financial borrowings. Lease liabilities totaled $16.2 million. Gross margin is not presented.
Material changes and unusual items
- In February, Entrada closed its Vertex collaboration and license agreement, receiving a $223.7 million upfront payment; Vertex separately invested $26.3 million for 1,618,613 shares at $16.26 per share. The agreement covers an exclusive worldwide license to ENTR-701 and a four-year research collaboration.
- Q1 collaboration revenue of $25.3 million included $4.9 million of research-cost reimbursement and $20.4 million recognized from amounts deferred at deal inception. $211.6 million remained deferred at quarter end and is expected to be recognized as research services are performed.
- Operating cash flow turned positive largely because of the upfront payment and the resulting deferred revenue, rather than recurring operating cash generation. Investing cash use was $40.4 million and financing cash provided was $19.5 million.
- R&D expense rose with increased internal staffing and facilities, Vertex-program work, and an OSIF sublicense fee. The $2.8 million fee was accrued in Q1 and paid in April.
- The $3.6 million tax expense was driven largely by the projected current tax liability related to tax recognition of the Vertex upfront payment, despite a pretax loss.
Outlook, risks and contingencies
- Management expects cash, cash equivalents and marketable securities, together with ongoing Vertex research support and anticipated milestone payments, to extend the cash runway into the second half of 2025. The estimate depends on assumptions and milestone achievement; the financial-statement note separately states resources should fund operations for at least 12 months from issuance.
- Management expects continued operating losses and negative operating cash flows for the foreseeable future, with R&D and other costs increasing as programs advance. Additional financing may be needed.
- The FDA placed the ENTR-601-44 IND on clinical hold and requested additional information. Entrada was working to resolve the hold and exploring global options toward a healthy-volunteer trial in 2023. It planned to submit an IND for ENTR-601-45 in Q4 2024.
- All programs remain preclinical or in discovery, and EEV is a novel, unproven approach. Key risks include regulatory and clinical delays, safety or efficacy failures, manufacturing and third-party dependency, funding needs, competition, and intellectual-property protection.
- The Vertex agreement provides up to $485.0 million in research, development, regulatory and commercial milestones, plus tiered royalties in the mid- to high-single digits on potential future net sales. Milestones were excluded from the recognized transaction price at quarter end because achievement was not considered probable.
- Entrada amended its 6 Tide Street lease, reducing the space subject to rent by November 2023; the remaining lease runs through November 2025. The new IDB headquarters lease commenced for accounting purposes in April 2023 and was not included in March-quarter lease liabilities.
- No material litigation was reported. Management concluded disclosure controls were effective as of March 31, 2023, and reported no material change in internal control over financial reporting during the quarter.
Investor verification priorities
- Track FDA interactions and the timing and conditions for lifting the ENTR-601-44 clinical hold, including whether a trial begins in the U.S. or elsewhere.
- Verify Vertex research progress, cost reimbursements, deferred-revenue recognition, and any milestone achievement; assess the agreement’s termination provisions and Entrada’s dependence on Vertex for ENTR-701 development and commercialization.
- Monitor cash burn excluding collaboration upfront proceeds, spending growth, and whether the stated second-half-2025 runway assumptions remain achievable.
- Review the $3.6 million tax expense and future tax cash requirements associated with collaboration revenue and R&D tax rules.
- Assess dilution from the Vertex share issuance and equity compensation, and monitor lease costs and obligations as the new headquarters lease takes effect.